Compare Hyatt Hotels Corporation (H) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Incyte Corporation — how do they compare? Hyatt Hotels Corporation trades at $172.22 (market cap $16.27B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| H | INCY | |
|---|---|---|
Market Cap | $16.27B | $24.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $129.93 |
52-Week Low | $135.42 | $81.61 |
Enterprise Value | $20.17B | $20.04B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $178.25, up 4.8% over 24 hours, near its 52-week high of $206.86. The stock shows a bearish technical signal despite recent earnings beats, with Q2 2026 EPS of $1.12 surpassing the $0.913 estimate. Fundamentals reveal a high P/E ratio of 213.14 and thin net income margin of 1.1%, though revenue grew to $7.10B in 2025. Analyst consensus is a 'Hold' with a $199.55 price target, while recent news highlights valuation concerns amid fee growth and RevPAR gains.
Outlook is mixed: strong fee growth and a record pipeline support expansion, but high valuation, project delays, and debt pose risks. The stock offers potential from operational momentum, yet investors face headwinds from regional weakness and rich multiples. Net cash flow turned negative in 2025, underscoring financial pressure despite EBITDA growth.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
